Features
Combating Inappropriate Polypharmacy
Older adults are especially prone to inappropriate polypharmacy because they commonly have multiple medical problems and see a variety of specialists.
Your search for parkinsonism returned 418 results
Drugs in the Pipeline
FDA Rejects Pimavanserin sNDA for Alzheimer Disease Psychosis
The sNDA for Alzheimer disease psychosis included data from the phase 3 HARMONY and phase 2 Study-019 trials.
News
Monoclonal Antibodies No Better Than Placebo for Early Parkinson Disease
Two studies show lack of benefit in primary or secondary end points with cinpanemab or prasinezumab versus placebo
News
COVID-19 Linked to Increased Risk of Neurological Disorders
Most neurological disorders do not appear to be more frequent after COVID-19 than after influenza or bacterial pneumonia
News
Early Use of RAAS Inhibitors May Benefit Children With Lupus Nephritis
Real-world data on use of RAAS inhibitors can be used to support future pragmatic studies to optimize management of childhood-onset SLE, according to investigators.
Drugs in the Pipeline
FDA Panel Votes on Pimavanserin for Alzheimer Disease Psychosis
Although not bound by the committee’s recommendations, the Agency does take them into consideration when making decisions on approval.
Drugs in the Pipeline
May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Drugs in the Pipeline
NDA Submitted for Continuous SC Infusion Therapy for Parkinson Disease
ABBV-951 is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous infusion.
Drugs in the Pipeline
Ampreloxetine Misses Endpoint in Second Neurogenic Orthostatic Hypotension Trial
The phase 3 REDWOOD study included patients aged 30 years and older with primary autonomic failures and symptomatic neurogenic orthostatic hypotension.
News
Older Adults Using Statins Have Reduced Risk of Parkinsonism
Lower risk of parkinsonism partly mediated by reduced odds of brain atherosclerosis
